Concerns about patient safety, reports of increased suicidal thinking and allegations of flawed research are at the heart of a new complaint to Health Canada over the much-hyped clinical trials for the use of MDMA to treat post-traumatic stress disorder.
'Brave' Calgary boy saved others from U.S. child predator, police sayMorneau says government willing to compensate Kinder Morgan against political delaysCAQ immigration plan sets 3-year deadline on learning French, passing values test'Brave' Calgary boy saved others from U.S. child predator, police sayComplaints about Thunder Bay Amber Alert from other parts of the province 'disheartening': OPP
0 comments:
Post a Comment